Does magnesium sulfate delay the active phase of labor in women with premature rupture of membranes? A randomized controlled trial  by Mirzamoradi, Masoumeh et al.
lable at ScienceDirect
Taiwanese Journal of Obstetrics & Gynecology 53 (2014) 309e312Contents lists avaiTaiwanese Journal of Obstetrics & Gynecology
journal homepage: www.t jog-onl ine.comOriginal ArticleDoes magnesium sulfate delay the active phase of labor in women
with premature rupture of membranes? A randomized controlled trial
Masoumeh Mirzamoradi a, Marzieh Behnam b, Tayebeh Jahed c, Soraya Saleh-Gargari d, *,
Mahmood Bakhtiyari e, f
a Department of Perinatology, Infertility and Reproductive Health Research Center (IRHRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran
b Infertility and Reproductive Health Research Center (IRHRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran
c Department of Gynecology and Obstetrics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
d Department of Perinatology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
e Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
f Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Irana r t i c l e i n f o
Article history:
Accepted 25 June 2013
Keywords:
delay
labor
magnesium sulfate
premature
Tehran* Corresponding author. Infertility and Reproduct
(IRHRC), Shahid Beheshti University (SBMU), Evin, 3
P.O. Box 1985717413, Tehran, Iran.
E-mail address: soraya_saleh2000@yahoo.co.uk (S
http://dx.doi.org/10.1016/j.tjog.2013.06.014
1028-4559/Copyright © 2014, Taiwan Association of Oa b s t r a c t
Objective: Administration of many drugs including magnesium sulfate (MS) has considerable inﬂuences
on pregnancy outcomes. The present study investigates the effects of MS administration on reaching the
active phase of labor in women with premature rupture of membrane (PROM) and subsequent fetal
complications.
Materials and methods: A double blind, randomized, placebo-controlled trial was performed among
primipara women referred to the PROM center in Tehran, Iran between March 2010 and August 2012.
Patients were equally allocated into two groups; the intervention group who received MS (n ¼ 46) and
the control (placebo) group (n ¼ 46). Both groups received a corticosteroid, 1g oral azithromycin (oral)
and 2 g ampicillin (IV) every 6 hours for 48 hours, followed by amoxicillin (500 mg orally 3 times daily)
for an additional 5 days. None of the research staff were aware of the treatment allocation of patients in
order for blinding purposes.
Results: Administration of MS in intervention group increases this period 2.7 times compared to the
control group. In women whose gestational age was <30 weeks, MS administration increased the active
phase of labor up to 77%. Administration of magnesium sulfate reduced the risk of respiratory distress
syndrome signiﬁcantly (p ¼ 0 .002), without producing any adverse pregnancy outcomes.
Conclusion: Magnesium sulfate increases delay in reaching the active phase of labor in mothers with
PROM, without producing adverse birth outcomes. (Registration ID in IRCT; IRCT2012091810876N1).
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Preterm labor refers to progressive cervical dilatation or
effacement associated with regular uterine contractions (6/hour)
[1]. It is an imperative factor in infant deaths and the second cause
of infant mortality followed by congenital anomalies [2,3]. Prema-
turity or gestational age <37 weeks is an essential health indicator
for all communities. Unfortunately despite progress made inive Health Research Center
rd ﬂoor, Taleghani Hospital,
. Saleh-Gargari).
bstetrics & Gynecology. Publishedidentifying causes of preterm labor, it has increased in recent years
[2,4].
Abortion, history of cesarean section, and preeclampsia are re-
ported to be the signiﬁcant causes of preterm labor [5]. Different
treatment methods have been evaluated to prevent preterm birth,
all of which have been used to delay preterm labor and reduce fetal
complications [6]. Pharmacological inhibition of premature uterine
contractions is among the widely available methods, but there is
still discrepancy regarding the treatment of choice [7e9].
Magnesium sulfate, prostaglandin inhibitors, calcium channel
blockers, and nitric oxide-releasing drugs have shown positive ef-
fects on preterm birth [10]. The use of tocolytics such asmagnesium
sulfate is one of the regular treatments to prevent preterm labor.
However, there is little published clinical evidence on its beneﬁcialby Elsevier Taiwan LLC. All rights reserved.
Table 1
Characteristics of intervention and control groups.
Variable Groups Mean ± SD p
Age (y) Intervention 26.85 ± 5.1 0.92
Control 26.96 ± 5.7
Gestational age (wk) Intervention 30.94 ± 1.77 0.12
Control 31.54 ± 1.8
History of abortion (%) Intervention 26.1 0.31
Control 17.4
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for at least 48 hours [13]. Generally there is a little controversial
information regarding utility of MS in case of premature rupture of
membrane (PROM). A meta-analysis in 2009 showed that MS
administration is not able to reduce the frequency of deliveries
within 48 hours, 7 days, or earlyelate preterm birth. The authors
concluded that no other tocolytic class resulted in improved
newborn outcomes when compared with MS tocolysis and it is
suitable to hold back MS tocolysis from women with recurrent
preterm labor afterwards [14].
The present randomized control trial aimed to investigate the
effects of magnesium sulfate on delay in reaching the active phase
of labor in women with PROM and subsequent fetal complications
in the Iranian population.
Materials and methods
It was a randomized control trial conducted in the Mahdieh
Medical Centre, Tehran, Iran betweenMarch 2010 and August 2012.
Inclusion criteria were: (1) pregnant women with gestational
age < 34 weeks who were hospitalized for premature rupture and
labor complaints; (2) the absence of concomitant disease such as
chorioamnionitis or a history of drug sensitivity to magnesium
sulfate; (3) no previous use of magnesium sulfate in order to curb
labor complaint in a recent pregnancy; and (4) the absence of twin
or multiple pregnancy. Exclusion criteria were: (1) probable case of
chorioamnionitis; (2) progress of labor as 4 cm cervical dilatation;
(3) allergy or medical complications in combination with magne-
sium sulfate; (4) fatal fetal anomalies; (5) nonreassuring fetal sta-
tus; (6) severe fetal growth restriction; (7); severe preeclampsia or
eclampsia; and (8) maternal hemorrhage with hemodynamic
instability. Cases and controls were matched in terms of expecting
their ﬁrst child, maternal age, gestational age (weeks), and a history
of abortion. Study population included all women expecting their
ﬁrst child and referred to the Center with preterm PROM. Patients
were allocated into two groups; intervention (magnesium sulfate,
n ¼ 46) and control (placebo, n ¼ 46).
According to inclusion criteria, duration of study, and the type of
researchdesign inwhich randomallocationwasused asamechanism
for control of known and unknown confounding variables, matching
was based on mentioned factors and other variables were ignored.
In this study, premature rupture was deﬁned as fetal membrane
rupture prior to 34 weeks of gestational age. Tocolytic medication
referred to those drugs which inhibit uterine contractions. Preterm
labor referred to persistent uterine contractions (e.g., at least 4
every 20minutes or 8 every 60minutes) with premature rupture of
membranes or cervical dilation of 1e3 cm or effacement exceeding
50% or a change in cervical dilation or effacement detected by serial
examinations.
For calculation of sample size, the Gehan and similar studies
were used considering a maximum of 5% error and 80% power
[15,16]. After determining sample size and statistical population, 92
patients were selected randomly fromwomen expecting their ﬁrst
child who had been referred to Mahdieh Hospital, Tehran, Iran. For
random allocation, treatment diets (intervention and control
groups) were packed in separate packages and coded from 1 to 92
by an expert midwife. When an eligible patient was accepted into
the study, another expert interviewed her and a code from 1 to 92
was assigned to questionnaires regardless of medicinal packages
coding. Finally, those who had an odd code were allocated to the
intervention group and others to the control group.
Placebo used in this study was prepared by the School of
Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran,
Iran. None of the research staff were aware of the treatment allo-
cation of patients in order for blinding purposes. In the interventiongroup, patients received 4 g of magnesium sulfate dissolved in
100 mL of normal saline solution for 20 minutes to reach loading
dose. Then, they received 2 g of magnesium sulfate dissolved in
100 mL of normal saline by infusion every hour. Infusion was
continued until 24 hours after complete cessation of uterine con-
tractions [17]. All steps were considered blinding principles in the
control group too. Both groups received a corticosteroid, 1g of oral
azithromycin and ampicillin 2 g intravenously every 6 hours for 48
hours, followed byamoxicillin (500 mg orally 3 times daily) for an
additional 5 days. During treatment, regular examinationwas done
hourly to measure respiratory and urinary volume, Glasgow Coma
Scale (GCS), Deep Tendon Reﬂex (DTR), fetal and maternal tachy-
cardia, body temperature, and malodorous vaginal discharge to
avoid fetal and maternal complications and consequences.
Data collection tool included a questionnaire which was
completed by two trained midwives. This questionnaire contained
information onmaternal age, gestationweeks, pregnancy gravidity,
having or not having a birth within 48 hours after drug adminis-
tration, fetal and maternal complications, and birth weight.
Prior to entering the study, all patients were informed and
consented to participate in the research. They were also allowed to
be excluded from the research whenever they wished.
Data description was done using descriptive statistics including
mean, standard deviation, variance, and frequency distribution
tables. The impact of medication on delay time was determined by
analytical statistics including Student t test, ManneWhitney, and
regression analysis. All analyses were conducted using SPSS soft-
ware version 20 (SPSS Inc.,Chicago, IL, USA).
This research was approved by the Ethics Committee in the
Shahid Beheshti University of Medical Sciences, Tehran, Iran.Results
In this study two groups including 46 patients receiving mag-
nesium sulfate (intervention) and 46 patients receiving placebo
(control) were used to determine the effects of medication on delay
in the active phase of labor and fetal complications. Mean age and
standard deviations was 26.9 ± 3.5 years. The majority of patients
(74.2%) had academic levels of education. There was no signiﬁcant
difference between cases and controls in terms of education levels
(p¼ 0.76). In terms of employment,14% of patients were clerks, 24%
service workers and shop keepers, 11% professionals, 19% in
elementary occupations, and the rest (32%) were housewives.
Table 1 represents basic characteristics of the two groups prior to
intervention. There was no signiﬁcant statistical difference in basic
characteristics between the two groups. Moreover, according to
linear and logistic regression analyses, with matching patient's age
and her gestational age, only magnesium sulfate was effective in
the delay of the active phase of labor (Table 2). The administration
of magnesium sulfate in women with preterm labor pain leads to
inhibition of uterine contractions and delay in delivery for at least
48 hours. Administration of magnesium sulfate in the intervention
group increases this period 2.7 times the same as in the control
group. In women with gestational age <30 weeks, magnesium
Table 2
Effects of magnesium sulfate and placebo on delay of the active phase of labor.
Group Variable Linear regressiona Logistic regressionb
SC 95% CI AOR 95% CI
Intervention Age (y) 0.119 1.4e3.4 0.95 0.86e1.4
Gestational
age (wk)
0.07 1.83e0.92 1.25 0.95e1.6
Magnesium
sulfate
(yes/no)
0.631 0.32e1.8 7.2 2.25e10.1
History of
abortion
(yes/no)
0.13 1.7e5.4 0.89 0.28e2.8
Control Age (y) 0.6 0.8e2.2 0.88 0.8e2.1
Gestational
age (wk)
0.11 0.7e1.1 1.1 0.7e1.7
Placebo
(yes/no)
0.161 0.5e1.5 2.2 0.8e3.4
History of
abortion
(yes/no)
0.11 1.2e4.4 0.44 0.7e1.8
AOR ¼ adjusted odds ratio; CI ¼ conﬁdence interval; SC ¼ standardized coefﬁcient.
a Delay time in continuous scale as dependent variable.
b Delay time in categorical scale as dependent variable.
Table 3
Demographic information of two groups of quantitative and qualitative variables.
Variable, mean ± SD or n (%) Intervention Control p
Age of mother (y) 26.85 ± 5.13 26.99 ± 5.6 0.92
Gestational age (wk) 30.95 ± 1.78 31.54 ± 1.78 0.12
Latency (h) 114.1 ± 39.2 20.9 ± 18.8 >0.001
1st min Apgar 8.17 ± 1.39 8.04 ± 1.35 0.64
5th min Apgar 9.22 ± 1.6 9.22 ± 1 0.98
Birth weight (g) 1688.7 ± 560 1828 ± 541 0.23
History of abortion (yes/no) 12 (26.1) 8 (17.4) 0.31
RDS 14 (30.4) 29 (63) 0.002
Need NICU 32 (96.6) 34 (73.9) 0.64
IVH2 2 (4.3) 3 (6.5) 0.64
Infant death 1 (2.2) 3 (6.5) 0.30
Sepsis 5 (10.9) 8 (17.4) 0.37
Uterine atony 2 (4.3) 0 (0) 0.11
Chorioamnionitis 0 (0) 0 (0) e
IVH2 ¼ intraventricular hemorrhage; NICU ¼ neonatal intensive care unit;
RDS ¼ respiratory distress syndrome.
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change has been 87.7% and 72.7% in womenwith 30e31 weeks and
32e33 weeks of gestational age (Table 3).
Administration of magnesium sulfate not only did not lead to
adverse pregnancy outcomes, but also had positive effects in
reducing respiratory distress syndrome (p ¼ 0.002). Considering
the impact of mentioned variables on fetal complications, logistic
regression results showed that administration of magnesium sul-
fate has no effects on fetal complications (Table 4).Table 4
Effects of variables on neonatal outcomes.
Variable Neonatal outcomes (OR, 95% CI)
Death Sepsis
Age of mother (y) 1.41 (0.7 ± 2.2) 0.9 (0.75e1.1)
Gestational age (wk) 0.8 (0.4e1.6) 1.02 (0.92e1.13)
Latency (h) 1.18 (0.9e1.32) 0.99 (0.97e1.01)
1st min Apgar 0.7 (0.4e1.4) 1/14 (0.18e6.9)
5th min Apgar 0.9 (0.6e1.8) 1.65 (0.2e4)
Birth weight (g) 0.9 (0.62e1.17) 0.97 (0.95e0.99)
History of abortion (yes/no) 1.008 (0.7e1.46) 0.26 (0.04e1.1)
Administration of MS (yes/no) 2.23 (0.8e3.26) 4.54 (0.8e6.7)
CI ¼ conﬁdence interval; IVH ¼ intraventicular hemorrhage; MS ¼ magnesium sulfate;
syndrome.The weight variable has a positive effect at birth and prevents
sepsis, so that every unit increase in weight will decrease the
chances of infection by 0.3%. Regarding respiratory distress
syndrome (RDS) outcome, it should be mentioned that the only
effective variable is administration of magnesium sulfate which
shows a strong protective effect. As a result, the chance of res-
piratory distress syndrome in infants who had received mag-
nesium sulfate was 80% less than those who had received
placebo. By every unit increase of gestational age, the probability
to need care in neonatal intensive care unit (NICU) was
decreased by 33%.Discussion
Magnesium sulfate is an effective blocker in women with pre-
mature rupture to delay reaching the active phase of labor. In this
study, all patients were matched in basic characteristics including
age, gestational age, history of abortion, and educational level, so
the results are less inﬂuenced by patients' characteristics. Mothers
at gestational age between 16 weeks and 36 weeks are at greater
risk for having premature pregnancies. This risk increases with less
gestational age and having a history of more premature pregnan-
cies [18]. In recent years, efforts have been made to provide better
treatment strategies.
The regression analyses with regard tomaternal age, gestational
age, and a history of abortion showed that the administration of
magnesium sulfate leads to at least 48 hours delay in the active
phase of labor (OR ¼ 27, 95% CI ¼ 45.51.10). These ﬁndings indi-
cate that the chance of delay in reaching the active phase of labor
for those who have received magnesium sulfate was 2.7 times
higher than the corresponding conditions for the control group.
Other studies have conﬁrmed the effects of magnesium sulfate on
delay in reaching the active phase of labor [13,19]. Consumption of
magnesium sulfate in women with gestational age <33 weeks has
led to 77% increase in the active phase of labor (Fig. 1). However, in
Agudelo overview which has been done on six clinical trials, the
results indicate a signiﬁcant reduction of cerebral palsy (OR ¼ 0.69,
CI ¼ 0.550.88) following the consumption of magnesium sulfate
[20], whereas it is known as a strong risk factor in the Mittendorf
study. Moreover, this study states that the drug leads to more fetal
complications [7] even though, preterm delivery itself is a risk
factor and is associated with the choice of treatment, gestational
age, and maternal age [21].
Many studies have been conducted regarding other outcomes
associated with preterm delivery in the presence or absence of
preterm premature rupture. For example, a study showed that the
use of magnesium sulfate had reduced the risk of death in pre-
mature infants [22], but in the next study it had increased this risk
[23]. Other studies have shown no signiﬁcant difference in cho-
rioamnionitis, birth weight, and frequency of days hospitalized inRDS IVH NICU
1.03 (0.94e1.12) 0.87 (0.68e1/11) 1.07 (0.93e1.2)
1 (0.95e1.06) 0.9 (0.8e1.3) 0.67 (0.53e0.84)
0.98 (0.7e1.2) 1.004 (0.99e1.02) 0.99 (0.98e1)
0.41 (0.14e1.16) 1.18 (0.5e2.1) 0.8 (0.67e1.2)
2.67 (0.87e3.24) 1.18 (0.11e1.91) 0.78 (0.54e1.05)
0.99 (0.98e1.1) 0.99 (0.98e1.02) 1 (0.99e1.02)
0.79 (0.25e2.5) 1.02 (0.3e1.41) 0.64 (0.2e3.9)
0.21 (0.08e0.6) 3.2 (0.4e4.8) 2.69 (0.54e5.21)
NICU ¼ neonatal intensive care unit; OR ¼ odds ratio; RDS ¼ respiratory distress
Fig. 1. Mean latency changes in the active phase of labor.
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lator, sepsis, mortality, hyaline membrane disease, necrotizing
enterocolitis, and intraventricular hemorrhage. There was no
improvement in prenatal prognosis [24].
In this study, fetal respiratory distress, requiring care in neonatal
intensive care unit (NICU), cerebral intra-ventricular hemorrhage,
infant death, and sepsis were considered as fetal outcomes. Ac-
cording to results, magnesium sulfate did not have any effects on
mentioned outcomes except RDS. The results of the present study
on the outcome of death are consistent with other studies [20].
Logistic regression results showed that birth weight does not have
protective effects to prevent sepsis, so that each unit increase in
weight reduces the chance of infection by 0.3%. Moreover, those
who had received magnesium sulfate had an 80% lesser chance of
RDS risk. There was no case of chorioamnionitis and adverse effects
of magnesium sulfate (Table 4). Given that risk factors for preterm
delivery and response to treatment, complications, and infant and
maternal mortality are different according to race and ethnicity,
decisions on requiring treatment and preventing preterm delivery
should be made separately based on each region's race, ethnicity,
medical facilities, care centers for infants, and NICUs. However, the
present study has tried to show real effects of magnesium sulfate in
an Iranian community. In this research, magnesium sulfate
increased the delay in reaching the active phase in mothers with
PROM and there was no evidence of adverse fetal outcomes.
However, due to different results and various studies, there was no
ﬁrm decision on use or nonuse of this drug to prevent adverse fetal
outcomes. Larger studies should be done with a focus on occur-
rence of fetal complications in women with preterm labor.
Conﬂicts of interest
The authors have no conﬂicts of interest relevant to this article.References
[1] How HY, Zafaranchi L, Stella CL, Recht K, Maxwell RA, Sibai BM, et al.
Tocolysis in women with preterm labor between 32 0/7 and 34 6/7 weeks
of gestation: a randomized controlled pilot study. AmJ Obstet Gynecol
2006;194:976e81.
[2] Ramsey P, Goldenberg R. Obstetric management of prematurity. In: Martin RJ,
Fanaroff AA, Walsh MC, editors. Fanaroff and Martin's Neonatal-Perinatal
Medicine. 8th ed. Philadelphia: Elsevier-Mosby; 2006. p. 331e9.
[3] Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews T, Kirmeyer S, et al.
Births: ﬁnal data for 2007. National vital statistics reports 2010;58:1e125.
[4] Ruiz RJ, Fullerton J, Dudley DJ. The interrelationship of maternal stress,
endocrine factors, and inﬂammation on gestational length. Obstet Gynecol
Surv 2003;58:415.
[5] Martius JA, Steck T, Oehler MK, Wulf KH. Risk factors associated with
preterm (< 37þ 0 weeks) and early preterm birth (< 32þ 0 weeks): uni-
variate and multivariate analysis of 106 345 singleton births from the 1994
statewide perinatal survey of Bavaria. Eur J Obstet Gynecol Reprod Biol
1998;80:183e9.
[6] Lemons JA, Bauer CR, OhW, Korones SB, Papile LA, Stoll BJ, et al. Very low birth
weight outcomes of the National Institute of Child Health and Human
Development neonatal research network, January 1995 through December
1996. Pediatrics 2001 Jan;107(1):E1.
[7] Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE,
et al. Association between the use of antenatal magnesium sulfate in preterm
labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002;186:
1111e8.
[8] Katz VL, Farmer RM. Controversies in tocolytic therapy. Clin Obstet Gynecol
1999;42:802.
[9] Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al.
A randomized, controlled trial of magnesium sulfate for the prevention of
cerebral palsy. N Engl J Med 2008;359:895e905.
[10] Allen SR. Tocolytic therapy in preterm PROM. Clin Obstet Gynecol
1998;41:842.
[11] Sanchez-Ramos L, Kaunitz AM, Gaudier FL, Delke I. Efﬁcacy of maintenance
therapy after acute tocolysis: a meta-analysis. Am J Obstet Gynecol 1999;181:
484e90.
[12] Berkman ND, Thorp Jr JM, Lohr KN, Carey TS, Hartmann KE, Gavin NI, et al.
Tocolytic treatment for the management of preterm labor: a review of the
evidence. Am J Obstet Gynecol 2003;188:1648e59.
[13] Tan T, Devendra K, Tan L, Tan H. Tocolytic treatment for the management of
preterm labour: a systematic review. Singapore Med J 2006;47:361.
[14] Mercer BM, Merlino AA. Society for Maternal-Fetal Medicine. Magnesium
sulfate for preterm labor and preterm birth. Obstet Gynecol 2009 Sep;114(3):
650e68. http://dx.doi.org/10.1097/AOG.0b013e3181b48336.
[15] Gehan EA. Clinical trials in cancer research. Environ Health Persp 1979;32:31.
[16] Hasan Zadeh Maliheh, Youseﬁ Z, Malakooti H. Preterm premature rupture of
membranes: Aggressive Tocolysis versus expectant management. Kowsar
Med J 2005;10(3):217e22.
[17] Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic
magnesium sulphate associated with increased total paediatric mortality?
Lancet 1997;350:1517.
[18] Iams JD, Berghella V. Care for women with prior preterm birth. Am J Obstet
Gynecol 2010;203:89e100.
[19] Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for
inhibiting preterm labour. Cochrane Database Syst Rev 2005;3:CD004452.
[20] Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention
of cerebral palsy in preterm infants less than 34 weeks' gestation: a sys-
tematic review and metaanalysis. Am J Obstet Gynecol 2009;200:595e609.
[21] Pasquier JC, Picaud JC, Rabilloud M, Claris O, Ecochard R, Moret S, et al.
Neonatal outcomes after elective delivery management of preterm premature
rupture of the membranes before 34 weeks' gestation (DOMINOS study). Eur J
Obstet Gynecol Reprod Biol 2009;143:18e23.
[22] Grether JK, Hoogstrate J, Selvin S, Nelson KB. Magnesium sulfate tocolysis and
risk of neonatal death. Am J Obstet Gynecol 1998;178:1e6.
[23] Scudiero R, Khoshnood B, Pryde PG, Lee KS, Wall S, Mittendorf R. Perinatal
death and tocolytic magnesium sulfate. Obstet Gynecol 2000 Aug;96(2):
178e82.
[24] How HY, Cook CR, Cook VD, Miles DE, Spinnato JA. Preterm premature rupture
of membranes: aggressive tocolysis versus expectant management. J Matern
Fetal Neonatal Med 1998;7:8e12.
